Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Finotonlimab + Bevacizumab in Resectable HCC
NCT07009470Active, not recruiting
- Sponsor
- Tongji Hospital
- Start
- Feb 2025
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of finotonlimab in hepatocellular carcinoma (HCC), sponsored by Tongji Hospital. Primary endpoints: 2-year Disease-Free Survival rate and 2-year Overall Survival rate. Started Feb 2025; status: active, not recruiting.
02
Drugs
finotonlimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07009470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07009470.